Organon announces the appointment of Ramona A. Sequeira to the company's Board of Directors, effective July 1, 2025.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Organon has announced the acquisition from Biogen of US regulatory and commercial rights for intravenous infusion of ...

The revision of the outlook to negative is due to the anticipation that Organon’s leverage will continue to be high over the next 12-18 months. This is attributed to limited near-term earnings growth ...

Morgan Stanley lowered the firm’s price target on Organon (OGN) to $15 from $16 and keeps an Equal Weight rating on the shares. The firm ...

Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise ... In addition to Organon’s current products, the company invests in innovative solutions and research to drive ...